Jifeng Feng

机构：Jiangsu Cancer Hospital, Nanjing Medical University · ORCID：0000-0001-6182-1142

发表论文 8 篇 · 总被引 186 次 · h-index 7

代表论文

• Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets (2022 · Cell Death Discovery · 被引 68)
• Lactylation in cancer: metabolic mechanism and therapeutic strategies (2025 · Cell Death Discovery · 被引 35)
• SAA suppresses α-PD-1 induced anti-tumor immunity by driving TH2 polarization in lung adenocarcinoma (2023 · Cell Death and Disease · 被引 25)
• CRNDE mediated hnRNPA2B1 stability facilitates nuclear export and translation of KRAS in colorectal cancer (2023 · Cell Death and Disease · 被引 18)
• AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure (2025 · Cell Death and Disease · 被引 11)
• Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1 (2024 · Cell Death and Disease · 被引 11)